Article Sidebar
Views PDF: 39
NGHIÊN CỨU MỐI LIÊN QUAN GIỮA KIỂU GEN SARS-CoV-2 VỚI MỘT SỐ ĐẶC ĐIỂM LÂM SÀNG Ở NGƯỜI BỆNH COVID-19
Main Article Content
Abstract
ABSTRACT
Objectives: COVID-19 has diverse clinical manifestations and new variants continuously appear. The study that determine relationship between SARS-CoV-2 genotype and some clinical characteristics in COVID-19 patients
Subjects and methods: 700 patients diagnosed with COVID-19 (from January 2021 to May 2022) had sequenced of SARS-CoV-2 genome using Illumina Miseq technology, then analyzed the relationship between variants with some clinical characteristics of COVID-19 patients.
Results: We collected 50 samples infected with Alpha, 350 samples infected with Delta and 300 samples infected with Omicron. Among the three variant groups: The Alpha variant group has the lowest average age (41.34 ± 17.58) and the most common symptom was diarrhea (p < 0.05). The Omicron variant group had significantly higher symptoms of dry cough and sore throat (76.0%) (p < 0.05). On the other hand, dyspnea (43.7%); smell disorders (5.7%) and taste disorders (2.6%) predominate in the Delta variant group. The rate of severe, critical illness and death was highest in the Delta variant group, following by the Omicron variant group and lowest in the Alpha variant group (p < 0.05).
Conclusion: The Alpha variant patients had the lowest average age among three variants. The common clinical symptom of the Alpha patients was diarrhea. Smell disorders; taste disorders and dyspnea were predominate in the Delta patients. Meanwhile, symptoms of sore throat; Dry cough and chest pain were the most common in the Omicron patients. Delta patients have higher risk of severe, critical illness level and rate of death than other variants.
Article Details
Keywords
SARS-CoV-2 variant, COVID-19
References
2. Quintero AM, Eisner M, Sayegh R, et al. Differences in SARS-CoV-2 clinical manifestations and disease severity in children and adolescents by infecting variant. Emerging Infectious Disease Journal. 2022; 28(11):2270.
3. Hyams C, Challen R, Marlow R, et al. Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom. Lancet Reg Health Eur. 2023; 25:100556.
4. Kandeel A, Moatasim Y, Fahim M, et al. Comparison of SARS-Cov-2 omicron variant with the previously identified SARS-Cov-2 variants in Egypt, 2020-2022: Insight into SARS-Cov-2 genome evolution and its impact on epidemiology, clinical picture, disease severity, and mortality. BMC Infectious Diseases. 2023; 23(1):542.
5. Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: A prospective observational study from the ZOE COVID Study. Lancet. 2022; 399(10335): 1618-1624.
6. Bálint G, Vörös-Horváth B, Széchenyi A. Omicron: Increased transmissibility and decreased pathogenicity. Signal Transduct Target Ther. 2022; 7(1):151.
7. Deng H, Lin H, Mai Y, et al. Clinical features and predictive factors related to liver injury in SARS-CoV-2 Delta and Omicron variant-infected patients. Eur J Gastroenterol Hepatol 2022; 34(9):933-939.
8. Do TV, Manabe T, Vu GV, et al. Clinical characteristics and mortality risk among critically ill patients with COVID-19 owing to the B.1.617.2 (Delta) variant in Vietnam: A retrospective observational study. PLoS ONE. 2023; 18(1):e0279713.
9. Ong SWX, Chiew CJ, Ang LW, et al. Clinical and virological features of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta). Clin Infect Dis. 2022; 75(1):e1128-e1136.
10. Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, COVID-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: Prospective observational study. Bmj. 2022; 376:e069761.